Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
AZ 5104 is an inhibitor of mutant EGFRs (IC50 = 2 nM for EGFRL858R/T790M and EGFRT790M for both) and an active metabolite of AZD 9291 (Item No. 16237).1 It is selective for these mutant EGFRs over wild-type EGFR (IC50 = 33 nM). AZ 5104 is formed from AZD 9291 by the cytochrome P450 (CYP) isoform CYP3A.2 It decreases proliferation of H1975 non-small cell lung cancer (NSCLC) cells containing the L858R activating and T790M resistance mutations (GI50 = 24 nM). AZ 5104 (2.5-10 mg/kg per day) reduces tumor growth in an H1975 mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem. 57(20), 8249-8267 (2014).
2. Metabolic disposition of osimertinib in rats, dogs, and humans: Insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab. Dispos. 44(8), 1201-1212 (2016).